Authors: Sarah Assali, DO & Nova Szoka, MD
WATS3D is a novel endoscopic device & imaging process made by CDx Diagnostics used to facilitate the detection of Barrettâs esophagus (BE) and esophageal dysplasia in hopes to prevent progression to esophageal adenocarcinoma. This device allows for surveillance of larger surface areas using a brushing technique that is quicker than traditional single forceps biopsies. The WATS3D utilizes 3D imaging and cytopathology for earlier detection of precancerous cells to allow for earlier intervention. This device also allows for recognition of crypt dysplasia, which is a newly identified pathological finding that has been found to be a risk factor for esophageal adenocarcinoma. The ability to sample larger surface area with a full-thickness decreases the sampling inconsistencies faced with standard forceps biopsy (FB) techniques.
A recent multicenter prospective trial enrolled patients with suspected BE and known BE undergoing surveillance. Both groups underwent WATS3D as an adjunct to targeted FB and random four-quadrant FB. The use of WATS3D increased the overall detection of low-grade dysplasia by 88.5%.1
Indications for WATS3D technology include patients undergoing endoscopic evaluation for upper gastrointestinal conditions such as: reflux disease, peptic ulcer disease, and screening or surveillance for Barrettâs esophagus.
Contraindications mirror the contraindications for upper endoscopy, including known perforated viscus.
1. Gross SA, Smith MS, Kaul V; US Collaborative WATS3D Study Group. Increased detection of Barrett’s esophagus and esophageal dysplasia with adjunctive use of wide-area transepithelial sample with three-dimensional computer-assisted analysis (WATS). United European Gastroenterol J. 2018 May;6(4):529-535. doi:10.1177/2050640617746298. Epub 2017 Nov 28. PubMed PMID: 29881608.